Kairos Pharma, LTD. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Kairos Pharma announced interim Phase 2 efficacy data for ENV-105 (carotuximab) combined with apalutamide in metastatic castration-resistant prostate cancer. Median progression-free survival was 17.7 months with combination therapy versus 2 months with apalutamide alone (P=0.0008). The company modified the protocol to enroll earlier-stage patients and targets Phase 2 completion by Q4 2027.
Why this rating
Pivotal interim efficacy readout for lead candidate at $6.9M-market-cap clinical-stage firm. Statistically significant PFS improvement is clinically meaningful; protocol expansion signals confidence. De-risks regulatory pathway materially.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.